Physician profile
Aaron M Miller
NPI 1104009307
$4,639.08
in general payments reported to CMS, 2019-2025
29 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,150 · 2020: $1,020 · 2023: $1,895 · 2024: $92.11 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,839 · Food and Beverage: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,839.00 |
| Food and Beverage | $630.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,920.65 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $413.15 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $354.21 | 2019-2025 | |
| Emd Serono, INC. | $219.62 | 2019 | |
| Lilly USA, LLC | $198.65 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Genentech USA, INC. | $173.63 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Pfizer INC. | $163.43 | 2023-2025 | |
| Genzyme Corporation | $157.34 | 2020-2025 | |
| Allergan, INC. | $153.36 | 2020 | |
| Supernus Pharmaceuticals, INC. | $136.62 | 2019-2020 | |
| Amgen INC. | $116.67 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $97.24 | 2019-2020 | |
| Orexo US, INC. | $82.47 | 2019-2020 | |
| Bausch Health US, LLC | $70.13 | 2019 | |
| Abbvie INC. | $59.79 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $49.91 | 2019 | |
| Sk Life Science, INC. | $34.63 | 2025 | |
| Ucb, INC. | $33.21 | 2019-2020 | |
| Livanova USA, INC. | $27.79 | 2019-2020 | |
| Janssen Biotech, INC. | $27.59 | 2025 | |
| Celgene Corporation | $23.84 | 2025 | Zeposia |
| Janssen Pharmaceuticals, INC | $20.07 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $18.92 | 2020 | |
| Boston Scientific Corporation | $15.95 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.29 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $14.17 | 2019 | |
| Neurocrine Biosciences, INC. | $14.13 | 2020 | |
| Mallinckrodt Hospital Products INC. | $13.62 | 2020 | |
| Alkermes, INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.